Biodesix Inc
NASDAQ:BDSX

Watchlist Manager
Biodesix Inc Logo
Biodesix Inc
NASDAQ:BDSX
Watchlist
Price: 1.28 USD 6.67% Market Closed
Market Cap: 186.2m USD
Have any thoughts about
Biodesix Inc?
Write Note

Biodesix Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biodesix Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Biodesix Inc
NASDAQ:BDSX
Stock-Based Compensation
$5.4m
CAGR 3-Years
13%
CAGR 5-Years
107%
CAGR 10-Years
N/A
DaVita Inc
NYSE:DVA
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CVS Health Corp
NYSE:CVS
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cigna Corp
NYSE:CI
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Laboratory Corporation of America Holdings
NYSE:LH
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biodesix Inc
Glance View

Market Cap
186.2m USD
Industry
Health Care

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.

BDSX Intrinsic Value
1.93 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Biodesix Inc's Stock-Based Compensation?
Stock-Based Compensation
5.4m USD

Based on the financial report for Dec 31, 2023, Biodesix Inc's Stock-Based Compensation amounts to 5.4m USD.

What is Biodesix Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
107%

Over the last year, the Stock-Based Compensation growth was -10%. The average annual Stock-Based Compensation growth rates for Biodesix Inc have been 13% over the past three years , 107% over the past five years .

Back to Top